Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
As a long time fake GP trolling account why are you always posting during surgery hours, ur not playing the part very well.
BTW the word is Troll and not Twoll my dumb bi-polar little troll.
Looser (as you use to say)
PI it's not NCYT's lousy management being questioned it's why they appear to not be required (under LSE rules) to inform shareholders. There has to be a gain or loss to the business by Eurofins acquiring Microgen significant enough to be RNS'ed. There is a difference in closing a business and selling it.
PI, it may well be a 'pump and dump' we'll find out Thurs/Friday. NCYT is an obvious target with a lot going on in an illiquid market. It's SP action and that's good, the SP notched up thanks to these traders, hope they carry on and keep doing higher lows all the way to 3.5. These people are just gambling, win some, lose some
No PI I think the SP is finding a floor 80p is the new 60p and I think there is a will to make it £1. If it can hold around here for the trading update aftermath I'd be happy. It's also it's a very illiquid market atm so doesn't take much to move the SP and for a little while now it keeps climbing back over 80p when it drops so it does look like enough people think sub 80p is a buy.
https://www.lse.co.uk/profiles/valju/?page=121
And then on the 6th April 2012 you abruptly stopped trolling the VAL board and started trolling the NCYT bb
Looks like Bio's dumped NCYT due to it's revenue dropping, also explains switching to disties for m&a
https://www.boursorama.com/bourse/actualites/biosynex-recul-de-49-du-chiffre-d-affaires-annuel-71d8fb608573fdef1239eb43274c1d26?symbol=1rPALBIO
"(CercleFinance.com) - Biosynex announces a turnover of 196.6 ME for 2022, down 49% compared to the previous financial year (-50% in organic terms excluding the effect of acquisitions during the financial year) .
The group indicates that it had to face, from the second quarter, a sharp decline in sales of Covid-19 products in Europe.
The drop thus represents more than 200 ME over the whole year, with Covid-19 products posting revenue of 140.9 ME in 2022 compared to 342.2 ME in 2021.
For 2023, the Group anticipates the continued decline in activity around Covid-19 products. “However, this activity remains resilient due to the endemic situation and the interest in the combined detection of viral respiratory infections (SARS-CoV-2, influenza, respiratory syncytial virus)”, specifies Biosynex."
If you peeked Sharestack you would see that a senior HR head has written several replies to reviews, including one concerning bullying by management. Also it's a mixed bag, not everyone is a disgruntled employee who got sacked. It's also the no.1 site of it's kind for the West (100mm visitors a month)
"Executive Assistant to Chief Executive Officer & Chief Financial Officer
Jan 12, 2023 - Executive Assistant
Recommend
CEO Approval
Business Outlook
Pros
Actively working on the COVID pandemic.
Cons
Heavy organisational changes throughout the last 12 months so company has downsized by 2/3."
https://www.glassdoor.com/Reviews/Employee-Review-Novacyt-Group-RVW72554915.htm
Interesting, reads like an internal promotion, but nothing on LinkedIn, as NCYT currently doesn't have a CEO they are EA to the CFO only atm, and must have been hired to the role by the CFO. Getting a bit comfy there JMcC.